|
|
Articles
by
Bradley T. Hyman |
Total Records (
3 ) for
Bradley T. Hyman |
|
 |
|
|
|
Reisa A. Sperling
,
Clifford R. Jack
,
Sandra E. Black
,
Matthew P. Frosch
,
Steven M. Greenberg
,
Bradley T. Hyman
,
Philip Scheltens
,
Maria C. Carrillo
,
William Thies
,
Martin M. Bednar
,
Ronald S. Black
,
H. Robert Brashear
,
Michael Grundman
,
Eric R. Siemers
,
Howard H. Feldman
and
Rachel J. Schindler
|
|
Amyloid imaging related abnormalities (ARIA) have now been reported in clinical trials with multiple therapeutic avenues to lower amyloid-β burden in Alzheimers disease (AD). In response to concerns raised by the Food and Drug Administration, the Alzheimers Association Research Roundtable convened a working group to review the publicly available trial data, attempts at developing animal models, and the literature on the natural history and pathology of related conditions. The spectrum of ARIA includes signal hyperintensities on fluid attenuation inversion recoverysequences thought to represent vasogenic edema and/or sulcal effusion (ARIA-E), as well as signal hypointensities on GRE/T2∗ thought to represent hemosiderin deposits (ARIA-H), including microhemorrhage and superficial siderosis. The etiology of ARIA remains unclear but the prevailing data support vascular amyloid as a common pathophysiological mechanism leading to increased vascular permeability. The workgroup proposes recommendations for the detection and monitoring of ARIA in ongoing AD clinical trials, as well as directions for future research. |
|
|
|
|
Niklas Mattsson
,
Ulf Andreasson
,
Staffan Persson
,
Hiroyuki Arai
,
Sat Dev Batish
,
Sergio Bernardini
,
Luisella Bocchio- Chiavetto
,
Marinus A. Blankenstein
,
Maria C. Carrillo
,
Sonia Chalbot
,
Els Coart
,
Davide Chiasserini
,
Neal Cutler
,
Gunilla Dahlfors
,
Stefan Duller
,
Anne M. Fagan
,
Orestes Forlenza
,
Giovanni B. Frisoni
,
Douglas Galasko
,
Daniela Galimberti
,
Harald Hampel
,
Aase Handberg
,
Michael T. Heneka
,
Adrianna Z. Herskovits
,
Sanna-Kaisa Herukka
,
David M. Holtzman
,
Christian Humpel
,
Bradley T. Hyman
,
Khalid Iqbal
,
Khalid Iqbal
,
Stephan A. Kaeser
,
Elmar Kaiser
,
Elisabeth Kapaki
,
Daniel Kidd
,
Peter Klivenyi
,
Cindy S. Knudsen
,
Markus P. Kummer
,
James Lui
,
Albert Llado
,
Piotr Lewczuk
,
Qiao-Xin Li
,
Ralph Martins
,
Colin Masters
,
John McAuliffe
,
Marc Mercken
,
Abhay Moghekar
,
Jose Luis Molinuevo
,
Thomas J. Montine
,
William Nowatzke
,
Richard O’Brien
,
Markus Otto
,
George P. Paraskevas
,
Lucilla Parnetti
,
Ronald C. Petersen
,
David Prvulovic
,
Herman P.M. de Reus
,
Robert A. Rissman
,
Elio Scarpini
,
Alessandro Stefani
,
Hilkka Soininen
,
Johannes Schroder
,
Leslie M. Shaw
,
Anders Skinningsrud
,
Brith Skrogstad
and
Annette Spreer
|
|
Background
The cerebrospinal fluid (CSF) biomarkers amyloid β (Aβ)-42, total-tau (T-tau), and phosphorylated-tau (P-tau) demonstrate good diagnostic accuracy for Alzheimers disease (AD). However, there are large variations in biomarker measurements between studies, and between and within laboratories. The Alzheimers Association has initiated a global quality control program to estimate and monitor variability of measurements, quantify batch-to-batch assay variations, and identify sources of variability. In this article, we present the results from the first two rounds of the program.
Methods
The program is open for laboratories using commercially available kits for Aβ, T-tau, or P-tau. CSF samples (aliquots of pooled CSF) are sent for analysis several times a year from the Clinical Neurochemistry Laboratory at the Molndal campus of the University of Gothenburg, Sweden. Each round consists of three quality control samples.
Results
Forty laboratories participated. Twenty-six used INNOTEST enzyme-linked immunosorbent assay kits, 14 used Luminex xMAP with the INNO-BIA AlzBio3 kit (both measure Aβ-(1-42), P-tau(181P), and T-tau), and 5 used Meso Scale Discovery with the Aβ triplex (AβN-42, AβN-40, and AβN-38) or T-tau kits. The total coefficients of variation between the laboratories were 13% to 36%. Five laboratories analyzed the samples six times on different occasions. Within-laboratory precisions differed considerably between biomarkers within individual laboratories.
Conclusions
Measurements of CSF AD biomarkers show large between-laboratory variability, likely caused by factors related to analytical procedures and the analytical kits. Standardization of laboratory procedures and efforts by kit vendors to increase kit performance might lower variability, and will likely increase the usefulness of CSF AD biomarkers. |
|
|
|
|
Bradley T. Hyman
,
Creighton H. Phelps
,
Thomas G. Beach
,
Eileen H. Bigio
,
Nigel J. Cairns
,
Maria C. Carrillo
,
Dennis W. Dickson
,
Charles Duyckaerts
,
Matthew P. Frosch
,
Eliezer Masliah
,
Suzanne S. Mirra
,
Peter T. Nelson
,
Julie A. Schneider
,
Julie A. Schneider
,
Bill Thies
,
John Q. Trojanowski
,
Harry V. Vinters
and
Thomas J. Montine
|
|
A consensus panel from the United States and Europe was convened recently to update and revise the 1997 consensus guidelines for the neuropathologic evaluation of Alzheimer's disease (AD) and other diseases of brain that are common in the elderly. The new guidelines recognize the pre-clinical stage of AD, enhance the assessment of AD to include amyloid accumulation as well as neurofibrillary change and neuritic plaques, establish protocols for the neuropathologic assessment of Lewy body disease, vascular brain injury, hippocampal sclerosis, and TDP-43 inclusions, and recommend standard approaches for the workup of cases and their clinico-pathologic correlation. |
|
|
|
|
|
|